Company Overview and News


Add BCART
to your dashboard

Headline News

Genomic Health And Biocartis Announce Agreement To Develop An Idylla IVD Oncotype DX Breast Cancer Test To Broaden Global Patient Access

2017-09-13 devicespace
REDWOOD CITY, Calif. and MECHELEN, Belgium, Sept. 13, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests  and Biocartis Group NV (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced an exclusive agreement to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Score® test on Biocartis' Idylla platform that can be performed locally by laboratory partners and in hospitals around the world.

Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access

2017-09-13 prnewswire
Strategic Collaboration Aimed at Exclusive Test Development and Commercialization of Proprietary Genomic Health Tests on the Idylla™ Platform

European Genetic Testing Market Estimated to Reach USD 1.8 Billion by 2021

2016-03-16 prnewswire
23andme, Abbott Molecular, Biocartis, Quest Diagnostics, Illumina and Luminex Expected to Exploit Favorable Government Regulations